VIENNA – making obeticholic acid the first agent proven to improve the course of this disease.
“There is no doubt that with these data we have changed the treatment” of nonalcoholic steatohepatitis (NASH),, of Inova Fairfax Medical Campus in Falls Church, Va., said at the meeting sponsored by the European Association for the Study of the Liver. “We are at a watershed moment” in NASH treatment, Dr. Younossi added in a video interview.
Until now “we have had no effective treatments for NASH. This is the first success in a phase 3 trial; obeticholic acid looks very promising,” commented, professor of experimental hepatology at the University of Birmingham (England).
Obeticholic acid (OCA), an agonist of thereceptor, already has Food and Drug Administration marketing approval for the indication of primary biliary cholangitis, a much rarer disease than NASH.